We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,141

Watch out for a wide omnibus (claim)
  • Minter Ellison
  • Australia
  • July 30 2015

Old-style 'omnibus claims' are often overlooked in patent infringement disputes. The usual assumption is that these claims are very narrow in scope

Pharmaceutical follow-on patents - maintaining market exclusivity in the pharmaceutical industry
  • FB Rice
  • Australia
  • July 28 2015

Often, a pharmaceutical does not earn revenue for a company until well into the patent term; sometimes this may be 15 years or more into the term

Spins a web, anytime, but only pays royalties until the expiry of the patent
  • King & Wood Mallesons
  • Australia, USA
  • July 22 2015

It is tempting to begin analysis of the recent US Supreme Court patent case Kimble v Marvel Enterprises by slinging around some Spiderman puns. After

Gene patents in Australian context
  • FAL Lawyers
  • Australia
  • July 15 2015

The High Court is in the process of hearing an appeal from the Full Federal Court concerning the patentability of isolated genetic materials in

IP round-up
  • Russell Kennedy
  • Australia
  • July 14 2015

A recent decision of the US Supreme Court confirmed that the inventor of a web-slinging glove is not entitled to demand royalties from patent

How to avoid damaging the right to sue for infringement when maximising your licensing value
  • Fisher Adams Kelly
  • Australia, USA
  • July 9 2015

When negotiating license agreements, technology managers often seek to “slice and dice” their intellectual property portfolio so that each licensee

Intellectual property - 9 July 2015
  • Baker & McKenzie
  • Australia
  • July 9 2015

The High Court is expected to deliver its much anticipated decision in D'Arcy v Myriad Genetics later this year determining whether isolated nucleic

Generic Health succeeds in invalidating patent for aripiprazole: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) 2015 FCA 634
  • King & Wood Mallesons
  • Australia
  • July 7 2015

Generic Health is perhaps a step closer to bringing its generic version of the antipsychotic drug aripiprazole to market in Australia after Justice

Inventive step: how high is the obviousness threshold?
  • Bird & Bird
  • Australia
  • July 2 2015

As part of the long running legal battle in Australia concerning the validity (and infringement) of a series of second generation patents in respect

Full Court dismisses Garford’s appeal and upholds decision that patent claims are invalid
  • Davies Collison Cave
  • Australia
  • July 2 2015

The Full Federal Court has dismissed an appeal by Garford against the decision by Yates J that claims of its patent were invalid, and that it made